Insider · CIK 0001143732
Robert Profusek
Files at CTS (CTS CORP), KOD (Kodiak Sciences Inc.). First filing -, latest -.
In brief
Robert Profusek files SEC Form 4 as director at CTS (CTS CORP), and also at KOD (Kodiak Sciences Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Robert Profusek has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | KOD Kodiak Sciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,731 | $0.00 | $0 | 17,731 | Jul 2, 2026 |
| Nov 6, 2025 | CTS CTS CORP | AGrant or award Common Stock | +3,500 | $0.00 | $0 | 101,742 | Nov 10, 2025 |
| Jun 30, 2025 | KOD Kodiak Sciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jul 2, 2025 |
| Nov 7, 2024 | CTS CTS CORP | AGrant or award Common Stock | +2,400 | $0.00 | $0 | 98,242 | Nov 8, 2024 |
Questions about Robert Profusek
Answered from the filings on this page, as of the latest one.
Is Robert Profusek buying or selling?
Robert Profusek has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Robert Profusek's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Robert Profusek has 0.
Where does Robert Profusek file Form 4?
Robert Profusek has filed Form 4 at CTS (CTS CORP); KOD (Kodiak Sciences Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.